A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group.

Trial Profile

A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Insulin resistance; Metabolic syndrome
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 31 Oct 2013 Planned number of patients changed from 120 to 138 as reported by ClinicalTrials.gov.
    • 06 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top